Physician profile
Mark Peter Pallis
NPI 1538219712
$27,095.45
in general payments reported to CMS, 2019-2025
15 companies · $4,577 in 2025
The $4,577 reported for 2025 was more than what 81% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $6,157 · 2021: $4,764 · 2022: $3,036 · 2023: $3,334 · 2024: $4,220 · 2025: $4,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,549 · Food and Beverage: $3,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,548.66 |
| Food and Beverage | $3,583.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $14,634.63 | 2019-2025 | |
| Medacta USA, INC. | $5,631.42 | 2023-2025 | Gmk Sphere, Amistem, Primary Shoulder |
| Novus Surgical Consultants | $2,341.03 | 2023-2025 | |
| Novus Surgical Solutions LLC | $1,235.49 | 2020-2021 | |
| Pacira Pharmaceuticals Incorporated | $982.56 | 2022 | |
| Globus Medical, INC. | $802.29 | 2025 | Excelsius Gps |
| Stryker Corporation | $747.80 | 2019-2025 | Mako, Accolade |
| Innovation Technologies INC | $159.13 | 2025 | Irrisept |
| Smith+Nephew, INC. | $151.13 | 2019 | |
| Depuy Synthes Sales INC. | $140.68 | 2022 | |
| US Implant Solutions, LLC | $138.04 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $53.86 | 2024 | |
| Intuitive Surgical, INC. | $34.18 | 2022 | |
| Djo, LLC | $33.33 | 2019 | |
| Heraeus Medical, LLC. | $9.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pallis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.